Best Practices and Research Advances in Thoracic Oncology: A Regional Series SE Asia Course 3: Driver Alterations in Lung Cancer-KRAS: The New (Old) Kid on the Block

Video Transcription

Video Summary

Ben Solomon, a medical oncologist, discusses targeting KRAS mutations in non-small cell lung cancer (NSCLC), particularly the G12C mutation found in 13% of Western patients and 5% in Asian populations. New therapies, including soteracib and adagracib, have been FDA-approved for these mutations, showing moderate improvement in progression-free survival. Challenges persist with resistance, requiring more potent inhibitors and combination strategies with immunotherapy. Innovative approaches, like targeting KRAS in its active GTP-bound state and pan-RAS inhibitors, are being explored to address diverse KRAS mutations and overcome resistance.

Asset Subtitle

Benjamin Solomon, MBBS, PhD

Keywords

KRAS mutations

non-small cell lung cancer

soteracib

adagracib

immunotherapy